Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LONGTERMS: Fingolimod Extension in MS
NCT01201356Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2010
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Started Sep 2010; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01201356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01201356.